Magnetic stimulation of several brain areas for negative symptoms of schizophrenia
Tests multi-site magnetic brain stimulation for negative symptoms of schizophrenia.
Plain-language title generated from the registry record
Registry title: Multi-target TMS for Schizophrenia Negative Symptoms
Key facts
- Where
- Shanghai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 16-45 with first-episode schizophrenia and ongoing negative symptoms. It tests a magnetic brain stimulation treatment (TMS).
- Age
- 16 to 45 years
- Sex
- All sexes
- Disease stage
- First-episode schizophrenia (DSM-5), with disease duration less than 5 years. PANSS Negative Symptom subscale score above 15, and at least one item score of 3 or more.
- Earlier treatment
- A stable medication regimen for at least 6 weeks before the baseline visit and throughout the study. Symptoms generally stable in the month before baseline. No modified electroconvulsive therapy (mECT) in the past 6 months.
Main reasons for not taking part
- Other current or lifetime psychiatric disorders
- Severe or unstable physical illness, such as epilepsy, stroke, heart disease or cancer
- Alcohol abuse in the last 30 days, or alcohol/drug dependence in the last 6 months
- Pregnant or breastfeeding women
- Intellectual disability (IQ < 70)
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 45 years old?
Source: NCT07559084, who can take part
Where in China
- Shanghai Mental Health CenterShanghai, ChinaContact: Huiru CuiNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shanghai Mental Health Center
- Trial code
- NCT07559084
- Record updated
- 10 September 2026
- Original description
This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol targeting the right orbitofrontal cortex (R-OFC), left dorsolateral prefrontal cortex (L-DLPFC), and left inferior parietal lobule (L-IPL) for negative symptoms of schizophrenia.Read full original descriptionShow less
Development of a Multi-target Transcranial Magnetic Intervention Technique for Negative Symptoms of Schizophrenia
This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol targeting the right orbitofrontal cortex (R-OFC), left dorsolateral prefrontal cortex (L-DLPFC), and left inferior parietal lobule (L-IPL) for negative symptoms of schizophrenia.
Inclusion: Outpatients or inpatients at the Department of Psychiatry, Shanghai Mental Health Center; Meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for first-episode schizophrenia (diagnosed using the Structured Clinical Interview for DSM-5, SCID-5); disease duration less than 5 years at enrollment; Male or female aged 16-45 years; Education duration ≥ 9 years; Stable medication regimen for at least 6 weeks prior to baseline visit and throughout the study period; psychiatric symptoms generally stable within 1 month prior to baseline visit; Participants and their guardians can understand and sign written informed consent; Total score on the PANSS Negative Symptom subscale (PANSS-N) > 15, and at least one item score ≥ 3.
Exclusion: Alcohol abuse within 30 days prior to the study or alcohol/drug dependence within 6 months prior to the study; participation in any clinical trial within 30 days prior to baseline; Current or lifetime psychiatric disorders as determined by SCID-5 assessment; Severe or unstable physical illnesses, including: neurological disorders (delirium, dementia, stroke, epilepsy, migraine, etc.), congestive heart failure, angina pectoris, myocardial infarction, arrhythmia, hypertension, hyperglycemia, malignant tumors, and immunocompromised conditions; No history of modified electroconvulsive therapy (mECT) within the past 6 months; Pregnant or breastfeeding women; Intellectual disability (IQ < 70).